company background image
AVIR

Atea PharmaceuticalsNasdaqGS:AVIR Stock Report

Market Cap

US$2.7b

7D

22.5%

1Y

n/a

Updated

25 Sep, 2021

Data

Company Financials +
AVIR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth6/6
Past Performance3/6
Financial Health6/6
Dividends0/6

AVIR Overview

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections.

Price History & Performance

Summary of all time highs, changes and price drops for Atea Pharmaceuticals
Historical stock prices
Current Share PriceUS$32.14
52 Week HighUS$18.72
52 Week LowUS$94.17
Beta0
1 Month Change5.21%
3 Month Change34.99%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO5.93%

Recent News & Updates

Shareholder Returns

AVIRUS PharmaceuticalsUS Market
7D22.5%0.5%0.1%
1Yn/a14.3%35.3%

Return vs Industry: Insufficient data to determine how AVIR performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how AVIR performed against the US Market.

Price Volatility

Is AVIR's price volatile compared to industry and market?
AVIR volatility
AVIR Beta0
Industry Beta0.64
Market Beta1

Stable Share Price: AVIR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: AVIR's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201249Jean-Pierre Sommadossihttps://ateapharma.com

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 that is in Phase I/IIa clinical trial for the treatment of chronic hepatitis C; and AT-889, an investigational, second-generation nucleoside pyrimidine prodrug and other compounds for the treatment of respiratory syncytial virus.

Atea Pharmaceuticals Fundamentals Summary

How do Atea Pharmaceuticals's earnings and revenue compare to its market cap?
AVIR fundamental statistics
Market CapUS$2.66b
Earnings (TTM)US$35.29m
Revenue (TTM)US$175.01m

75.4x

P/E Ratio

15.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AVIR income statement (TTM)
RevenueUS$175.01m
Cost of RevenueUS$93.82m
Gross ProfitUS$81.19m
ExpensesUS$45.90m
EarningsUS$35.29m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.43
Gross Margin46.39%
Net Profit Margin20.16%
Debt/Equity Ratio0%

How did AVIR perform over the long term?

See historical performance and comparison

Valuation

Is Atea Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AVIR ($32.14) is trading below our estimate of fair value ($510.23)

Significantly Below Fair Value: AVIR is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: AVIR is poor value based on its PE Ratio (75.4x) compared to the US Pharmaceuticals industry average (22.2x).

PE vs Market: AVIR is poor value based on its PE Ratio (75.4x) compared to the US market (17.9x).


Price to Earnings Growth Ratio

PEG Ratio: AVIR is poor value based on its PEG Ratio (1.3x)


Price to Book Ratio

PB vs Industry: AVIR is overvalued based on its PB Ratio (4.4x) compared to the US Pharmaceuticals industry average (3.2x).


Future Growth

How is Atea Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

58.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AVIR's forecast earnings growth (58.4% per year) is above the savings rate (2%).

Earnings vs Market: AVIR's earnings (58.4% per year) are forecast to grow faster than the US market (14.9% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: AVIR's revenue (44.8% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: AVIR's revenue (44.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AVIR's Return on Equity is forecast to be very high in 3 years time (62.8%).


Past Performance

How has Atea Pharmaceuticals performed over the past 5 years?

10.3%

Historical Pharmaceuticals & Biotech annual earnings growth


Earnings and Revenue History

Quality Earnings: AVIR has high quality earnings.

Growing Profit Margin: AVIR became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: AVIR has become profitable over the past 5 years.

Accelerating Growth: AVIR has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: AVIR has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).


Return on Equity

High ROE: AVIR's Return on Equity (5.9%) is considered low.


Financial Health

How is Atea Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: AVIR's short term assets ($871.1M) exceed its short term liabilities ($273.7M).

Long Term Liabilities: AVIR's short term assets ($871.1M) exceed its long term liabilities ($29.0K).


Debt to Equity History and Analysis

Debt Level: AVIR is debt free.

Reducing Debt: AVIR has not had any debt for past 5 years.

Debt Coverage: AVIR has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: AVIR has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Atea Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AVIR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AVIR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AVIR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AVIR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AVIR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.1yrs

Average management tenure


CEO

Jean-Pierre Sommadossi (65 yo)

9.17yrs

Tenure

US$2,886,987

Compensation

Dr. Jean-Pierre Sommadossi, Ph D., is a Founder of Atea Pharmaceuticals, Inc. and has been its Chairman, Director, Chief Executive Officer and President since July 2012 and had been its Treasurer. Dr. Somm...


CEO Compensation Analysis

Compensation vs Market: Jean-Pierre's total compensation ($USD2.89M) is below average for companies of similar size in the US market ($USD5.25M).

Compensation vs Earnings: Jean-Pierre's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: AVIR's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.


Board Members

Experienced Board: AVIR's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: AVIR only recently listed within the past 12 months.


Top Shareholders

Company Information

Atea Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Atea Pharmaceuticals, Inc.
  • Ticker: AVIR
  • Exchange: NasdaqGS
  • Founded: 2012
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.660b
  • Shares outstanding: 82.78m
  • Website: https://ateapharma.com

Number of Employees


Location

  • Atea Pharmaceuticals, Inc.
  • 125 Summer Street
  • Boston
  • Massachusetts
  • 2110
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/25 02:24
End of Day Share Price2021/09/24 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.